|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||95.49 - 98.13|
|52 Week Range||78.95 - 116.49|
|Beta (3Y Monthly)||0.98|
|PE Ratio (TTM)||18.62|
|Earnings Date||Jul 22, 2019 - Jul 26, 2019|
|Forward Dividend & Yield||2.12 (2.20%)|
|1y Target Est||99.06|
Quest Diagnostics Inc NYSE:DGXView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for DGX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding DGX totaled $10.61 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. DGX credit default swap spreads are near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SECAUCUS, N.J. , May 14, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly ...
SECAUCUS, N.J., May 13, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the UBS Global Healthcare Conference in New York. Steve Rusckowski, Chairman, President and CEO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors with a long-term horizong may find it valuable to assess Quest Diagnostics Incorporated's...
Health-care stocks have had a tough year so far. But Medtronic, UnitedHealth Group, and Quest Diagnostics are three for income investors to consider.
U.S. equities are coming under some pressure on Friday, as investors cool their heels after a run to new record highs. A surprisingly strong Q1 GDP report raised a lot of eyebrows and is calling into question hopes of Federal Reserve interest rate cuts. In fact, with energy prices rising powerfully in recent weeks, and with the economy catting a tailwind, further rate hikes cannot be dismissed.This whipsawing of sentiment is resulting in some profit-taking. And some sector rotation as well.Energy stocks, which have been hot, are cooling a bit after President Trump said he called OPEC and they are going to ramp production in response to its efforts to cut oil exports out of Venezuela and Iran. In their place, health care stocks are perking up.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 A-Rated Stocks That Are Under $10 Here are four health care stocks in the group that are worth a look now: Johnson & Johnson (JNJ) Click to EnlargeShares of Johnson & Johnson (NYSE:JNJ) look ready to push up and out of their three-month consolidation range with a challenge of triple-top resistance near the $140-a-share level. Watch for a move to the December high, which would be worth a gain of nearly 6% from here. The company announced earlier this week that it would increase its quarterly dividend by more than 5%.The company will next report results on July 16 before the bell. Analysts are looking for earnings of $2.42 per share on revenues of $20.3 billion. When the company last reported results on April 16, earnings of $2.1 beat estimates by 6 cents on a 0.1% rise in revenues. Align Technology (ALGN) Click to EnlargeShares of Align Technology (NASDAQ:ALGN), a medical device company behind products like Invisalign, are breaking out of a month-long flirtation with its 200-day moving average returning to levels not seen since late October. Watch for a return to the highs seen in September, which would be worth a gain of nearly 30% from here. * 5 Cheap Energy Stocks to Buy Under $10 The company will next report results on July 24 after the close. Analysts are looking for earnings of $1.5 per share on revenues of $596.3 million. When the company last reported on April 24, earnings of 89 cents per share beat estimates by 6 cents on a 25.7% rise in revenues. Quest Diagnostics (DGX) Click to EnlargeShares of Quest Diagnostics (NYSE:DGX) are pushing up and over their 200-day moving average, challenging the highs set back in November. This has set up a roll-up to the upper end of a sideways range that goes back to early 2017. Shares were recently upgraded by Jefferies analysts, who are looking for a price target of $107.The company will next report results on July 23 before the bell. Analysts are looking for earnings of $1.7 per share on revenues of $1.95 billion. When the company last reported on April 23, earnings of $1.40 beat estimates by 2 cents on a 0.4% rise in revenues. Henry Schein (HSIC) Click to EnlargeShares of Henry Schein (NASDAQ:HSIC), a provider of health care products and services to dental offices, is enjoying a share price breakout to levels not seen since early December. Powered with momentum from a move above both its 50-day and 200-day moving averages, watch for a challenge of recent highs near $70, which would be worth a gain of more than 10% from here. * 10 Automation Stocks to Buy for the 21st Century The company will next report on May 7 before the bell. Analysts are looking for earnings of 76 cents per share on revenues of $3.3 billion. When the company last reported on Feb. 20, earnings of $1.12 beat estimates by a penny on a 1.7% rise in revenues.As of this writing, William Roth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 5 Hot Dividend Stocks to Buy as the Weather Heats Up * 7 Dividend Stocks That Could Double Over the Next Five Years * 10 Stocks to Sell Before They Give Back 2019 Gains * 7 Cloud Stocks to Buy Now Compare Brokers The post 4 Health Care Stocks That Are Starting to Heat Up appeared first on InvestorPlace.
CORAL GABLES, FL / ACCESSWIRE / April 24, 2019 / If there was one industry to be aware of right now, it's the healthcare industry. Definitive Healthcare's 2019 Annual Healthcare Trends Survey cited these two factors as major drivers to the future growth of the market. Today we are highlighting: Teladoc Health, Inc. (TDOC), TELUS Corporation (TU) (TSX:T.TO), Quest Diagnostics Incorporated (DGX), Premier Health Group (PHGRF) (PHGI.CN).
climbed 7.4% to $91.50 Tuesday after the diagnostic testing company reported better-than-expected first-quarter earnings. "We're off to a good start in 2019, with solid volume growth from our expanded health plan access," said Steve Rusckowski, chairman, president and CEO. "As we anticipated, volume accelerated through the quarter, and we look forward to continued progress as a member of UnitedHealthcare's Preferred Lab Network beginning July 1.
Quest Diagnostics (DGX) currently concentrates on its core diagnostic information services business and tries to maintain discipline in capital deployment.
The Secaucus, New Jersey-based company said it had net income of $1.20 per share. Earnings, adjusted for one-time gains and costs, came to $1.40 per share. The results surpassed Wall Street expectations. ...
- First quarter revenues of $1.89 billion , up 0.4% from 2018 - First quarter reported diluted EPS of $1.20 , down 5.4% from 2018; and adjusted diluted EPS of $1.40 , down 7.9% from 2018 - Cash provided ...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Quest Diagnostics Incorporated and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Quest was among one of only fifteen companies in the Health Care Equipment and Services category to attain the designation. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Quest Diagnostics Incorporated (NYSE:DGX) as an investment opportunity by taking the expected future cash flows and discounting them t...
SECAUCUS, N.J., April 18, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States. The new STD test packages are the first to be offered directly by Quest Diagnostics or any other major national laboratory to allow individuals to purchase tests at their discretion.
GuideStone Capital Management President David Spika joins Yahoo Finance's Adam Shapiro, Julie Hyman, Jared Blikre, and MIT Professor Sinan Aral.